54 related articles for article (PubMed ID: 22053899)
1. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis.
Chandler CS; Bell MM; Chung SK; Veach DR; Fung EK; Punzalan B; Burnes Vargas D; Patel M; Xu H; Guo HF; Santich BH; Zanzonico PB; Monette S; Nash GM; Cercek A; Jungbluth A; Pandit-Taskar N; Cheung NKV; Larson SM; Cheal SM
Mol Cancer Ther; 2022 Jan; 21(1):125-137. PubMed ID: 34667111
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of [
Poulie CBM; Jørgensen JT; Shalgunov V; Kougioumtzoglou G; Jeppesen TE; Kjaer A; Herth MM
Molecules; 2021 Jan; 26(3):. PubMed ID: 33494416
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
[TBL] [Abstract][Full Text] [Related]
5. Pretargeting: A Path Forward for Radioimmunotherapy.
Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
8. Clearing and Masking Agents in Pretargeting Strategies.
Staudt M; Herth MM
Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111254
[TBL] [Abstract][Full Text] [Related]
9. "Click-to-Clear": A Strategy to Minimize Radioactivity from the Blood Pool Utilizing Staudinger Ligation.
Soni N; Sarkar S; Bhise A; Ha YS; Park W; Yu AR; Kumar V; Lim JE; Yoon YR; Yoo J
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986581
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge rare earth radiometals: prospects for cancer theranostics.
Sadler AWE; Hogan L; Fraser B; Rendina LM
EJNMMI Radiopharm Chem; 2022 Aug; 7(1):21. PubMed ID: 36018527
[TBL] [Abstract][Full Text] [Related]
11. The various therapeutic applications of the medical isotope holmium-166: a narrative review.
Klaassen NJM; Arntz MJ; Gil Arranja A; Roosen J; Nijsen JFW
EJNMMI Radiopharm Chem; 2019 Aug; 4(1):19. PubMed ID: 31659560
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
[TBL] [Abstract][Full Text] [Related]
14. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry.
Houghton JL; Membreno R; Abdel-Atti D; Cunanan KM; Carlin S; Scholz WW; Zanzonico PB; Lewis JS; Zeglis BM
Mol Cancer Ther; 2017 Jan; 16(1):124-133. PubMed ID: 28062708
[TBL] [Abstract][Full Text] [Related]
15. Monooxorhenium(V) complexes with 222-N
Demoin DW; Dame AN; Minard WD; Gallazzi F; Seickman GL; Rold TL; Bernskoetter N; Fassbender ME; Hoffman TJ; Deakyne CA; Jurisson SS
Nucl Med Biol; 2016 Dec; 43(12):802-811. PubMed ID: 27694058
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
17. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.
Knight JC; Cornelissen B
Am J Nucl Med Mol Imaging; 2014; 4(2):96-113. PubMed ID: 24753979
[TBL] [Abstract][Full Text] [Related]
18. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.
Thompson S; Ballard B; Jiang Z; Revskaya E; Sisay N; Miller WH; Cutler CS; Dadachova E; Francesconi LC
Nucl Med Biol; 2014 Mar; 41(3):276-81. PubMed ID: 24533987
[TBL] [Abstract][Full Text] [Related]
19. Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.
Bryan JN; Kumar SR; Jia F; Balkin ER; Lewis MR
Cell Biol Int; 2014 Feb; 38(2):187-97. PubMed ID: 24323360
[TBL] [Abstract][Full Text] [Related]
20. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.
Zeglis BM; Sevak KK; Reiner T; Mohindra P; Carlin SD; Zanzonico P; Weissleder R; Lewis JS
J Nucl Med; 2013 Aug; 54(8):1389-96. PubMed ID: 23708196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
